Upstream Bio (UPB) EBITDA Margin (2023 - 2026)
Upstream Bio (UPB) reported EBITDA Margin of -5474.51% for Q2 2026, down 746.13 percentage points from -4728.39% a year earlier and down 1261.17 percentage points from the prior quarter.
Powered by 
Analysis
Upstream Bio (UPB) EBITDA Margin (2023 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Upstream Bio's EBITDA Margin came in at -5375.87%, down 916.71 percentage points year-over-year; for FY2025, it was -5611.81%, down 2334.38 percentage points from FY2024.
- By year, EBITDA Margin came in at -3277.43% in FY2024 (-1594.48 pp) and -1682.94% in FY2023.
- Five-year quarterly EBITDA Margin spans a low of -6900.90% in Q4 2025 and a high of -2343.75% in Q1 2024.
- Year over year, EBITDA Margin gained in 1 of the last seven quarters, with an average year-over-year change of -1435.64 percentage points.
- Per Business Quant data, the three quarters before Q2 2026 came in at -4213.35% (Q1 2026), -6900.90% (Q4 2025) and -5532.65% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Upstream Bio | 290.29 Mn | 290.29 Mn | -3.29 Mn | -5,474.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5,474.51% |
| Mar 31, 2026 | -4,213.35% |
| Dec 31, 2025 | -6,900.90% |
| Sep 30, 2025 | -5,532.65% |
| Jun 30, 2025 | -4,728.39% |
| Mar 31, 2025 | -5,648.41% |
| Dec 31, 2024 | -4,285.32% |
| Sep 30, 2024 | -3,110.21% |
| Jun 30, 2024 | -3,436.67% |
| Mar 31, 2024 | -2,343.75% |
| Dec 31, 2023 | -3,181.33% |
API Access
Upstream Bio EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=UPB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "UPB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=UPB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();